Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC.

摘要: Non-small-cell lung cancer (NSCLC) is a major cause of death worldwide. Alterations in such genes as EGFR and ALK are considered important biomarkers NSCLC due to the existence targeted therapies with specific tyrosine kinase inhibitors (TKIs). However, resistance-related mutations can occur during TKI treatment, which often result therapy inefficacy. Liquid biopsies arise reliable tool for early detection these types alterations, allowing non-invasive follow-up patients. Furthermore, they be essential screening, initial diagnosis check surgery success. Despite great advantages liquid high input that next-generation sequencing (NGS) approaches provide this field, its use oncology still limited. With improvement assay sensitivity establishment clinical guidelines biopsy analysis, it expected will used routine procedures. This review focuses on usefulness patients means detect alterations disease management, highlighting impact NGS methods.